AXLA US05454B1052

Report

Delayed Nasdaq - 05/24 04:00:00 pm
1.6	USD		-7.51%

05/19	Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference	BU
05/09	Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept	MT
05/05	AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

05/18/2022	05/19/2022	05/20/2022	05/23/2022	05/24/2022	Date
1.6(c)	1.7(c)	1.74(c)	1.73(c)	1.6(c)	Last
20 275	11 720	15 086	10 890	24 352	Volume
+3.90%	+6.25%	+2.35%	-0.57%	-7.51%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2022	- - -
Net income 2022	-77,3 M - -
Net Debt 2022	23,3 M - -
P/E ratio 2022	-1,01x
Yield 2022	-

Sales 2023	- - -
Net income 2023	-89,7 M - -
Net Debt 2023	123 M - -
P/E ratio 2023	-1,18x
Yield 2023	-

Capitalization	84,1 M 84,1 M -
EV / Sales 2022	-
EV / Sales 2023	-
Nbr of Employees	59
Free-Float	76,3%

More Financials

Company

Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Companyâ€™s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate...

Sector

Biotechnology & Medical Research

Calendar

05/24 | 02:30pm

Presentation

More about the company

Ratings of Axcella Health Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

D+

More Ratings

All news about AXCELLA HEALTH INC.

05/19	Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference	BU
05/09	Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept	MT
05/05	AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re..	AQ
05/05	Axcella Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
05/05	Earnings Flash (AXLA) AXCELLA THERAPEUTICS Reports Q1 Loss $-0.46	MT
05/05	Axcella Reports First Quarter Financial Results and Provides Business Update	BU
04/13	Abbvie Vice Chairman Severino Departs for Flagship Pioneering	DJ
03/31	SVB Leerink Trims Axcella Health's Price Target to $9 From $10, Maintains Outperform Ra..	MT
03/31	Wedbush Trims Axcella Health's Price Target to $10 From $11, Keeps Outperform Rating	MT
03/30	AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re..	AQ
03/30	Axcella Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
03/30	AXCELLA HEALTH : Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ..	PU
03/30	TRANSCRIPT : Axcella Health Inc., Q4 2021 Earnings Call, Mar 30, 2022	CI
03/30	Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..	BU
03/30	Axcella Health Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

News in other languages on AXCELLA HEALTH INC.

05/05	Axcella Health Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 202..
03/30	Axcella Health Inc. annonce ses résultats pour l'année complète se terminant le 31 déce..
03/30	Axcella Health Inc. Le vérificateur remet en question la continuité de l'exploitation.
03/18	Axcella Health Inc. annonce des changements de direction
03/16	L'histoire montre que les actions peuvent résister au cycle de hausse des taux

More news

Analyst Recommendations on AXCELLA HEALTH INC.

05/09	Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept	MT
03/31	SVB Leerink Trims Axcella Health's Price Target to $9 From $10, Maintains Outperform Ra..	MT
03/31	Wedbush Trims Axcella Health's Price Target to $10 From $11, Keeps Outperform Rating	MT

More recommendations

Provided by Scoopnest.com

Analysis

History shows stocks can weather rate hike cycle